Evidence type
Explore PeptideScanner’s selected, source-linked ClinicalTrials.gov records by peptide, source year, and dated registry update.
770 selected, source-linked records.
32 profiles are connected to this evidence type.
770 distinct public records are cited.
Most recent source dates
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03811561 at 2026-09-09T19:17:17.089Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Petrelintide
PeptideScanner retained ClinicalTrials.gov record NCT06926842 at 2026-09-09T19:17:17.080Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was petrelintide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07247084 at 2026-09-09T19:17:17.101Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07662213 at 2026-09-09T19:17:17.121Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06439277 at 2026-09-09T19:17:17.406Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Dulaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06851962 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Mazdutide
PeptideScanner retained ClinicalTrials.gov record NCT07803705 at 2026-09-09T19:17:17.113Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was mazdutide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT07801664 at 2026-09-09T19:17:17.074Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
BPC-157
PeptideScanner retained ClinicalTrials.gov record NCT07803250 at 2026-09-09T19:17:17.410Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was bpc-157.
Source: ClinicalTrials.gov ↗
Mazdutide
PeptideScanner retained ClinicalTrials.gov record NCT07083154 at 2026-09-09T19:17:17.091Z. Its registry update date was 2026-09-02, and PeptideScanner's reviewed identity mapping was mazdutide.
Source: ClinicalTrials.gov ↗
Pemvidutide
PeptideScanner retained ClinicalTrials.gov record NCT07795164 at 2026-09-09T19:17:17.076Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was pemvidutide.
Source: ClinicalTrials.gov ↗
Connected profiles
2005–2026